A 12-week Double-blind, Randomized, Multicenter Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous AMG 334 Against Placebo in Adult Episodic Migraine Patients Who Have Failed Prophylactic Migraine Treatments
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Nov 2017
At a glance
- Drugs Erenumab (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms LIBERTY
- Sponsors Novartis; Novartis Pharmaceuticals
- 08 Nov 2017 Planned End Date changed from 22 Mar 2019 to 18 Jan 2019.
- 08 Nov 2017 Planned primary completion date changed from 22 Mar 2019 to 18 Jan 2019.
- 08 Nov 2017 Status changed from recruiting to active, no longer recruiting.